Overview

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

To our knowledge, there are no comparative studies on bacillus Calmette-Guerin (BCG) and intravesical chemotherapy addressing quality of life (QoL) issues. The aim of this study was to prospectively evaluate and compare the QoL of intermediate-risk non-muscle-invasive (NMIBC) patients treated with BCG or gemcitabine.

Phase:

Phase 2

Details

Lead Sponsor:

Azienda Ospedaliera San Giovanni Battista

Collaborators:

Universitätsklinikum Hamburg-Eppendorf
University of Eastern Piedmont
University of Turin, Italy

Treatments:

BCG Vaccine
Gemcitabine